· Health Care Equipment · S&P SmallCap 600
GKOS GLAUKOS $9.1B
No. iDose is a drug implant, not an intelligence offer.
1 of 15
Reach, Weight, and Proof.
Last updated score 31 AugLast review 29 OctLast earnings call 28 OctNext earnings call not posted yet
What they are doing
Glaukos is selling iDose TR and the rest of the dropless glaucoma and cornea line. The 10-K's only artificial-intelligence sentence is a risk factor: implementing AI and machine learning may create legal or reputational harm. The second-quarter release is sales and the pipeline, not an AI product. The 28 October 2026 call, including the questions, named no artificial-intelligence product. A keratoconus screener discussed elsewhere is not in use. The score stays 1.
Why the score
- Reach 0 not 1: no function on the chain.
- Weight 0 not 1: a risk line is not an experiment.
- Proof 1 not 0: the risk factor uses the words.
- Proof 1 not 2: not tied to a product or a process.
What would move it next quarter: A named intelligence layer in an eye product that is actually in use.
Open these first
Evidence
Risk factor: implementation of artificial intelligence and machine learning technologies may result in legal and regulatory risks, reputational harm, or other adverse consequences. The business description is dropless glaucoma, cornea, and retinal therapies, including iDose TR. No AI product is named.